An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
About the study
This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Completed Study IMR-SCD-102.
- Female subjects must not be pregnant, not be breast feeding, and be highly unlikely to become pregnant. Male subjects must be unlikely to impregnate a partner.
- Subjects must be capable of giving informed consent and reading and signing the informed consent form after the nature of the study has been fully explained to them
- Subjects must be willing and able to complete all study assessments and procedures and to communicate effectively with the investigator and site staff.
EXCLUSION CRITERIA
Exclusion Criteria:
- Subjects with Hb >12.5 g/dL or <6 g/dL
- Subjects with known active hepatitis B or hepatitis C, with active or acute event of malaria or who are known to be positive for human immunodeficiency virus (HIV)
- eGFR <50 mL/min
- AST/ALT > 3x the upper limit of normal
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Sickle Cell Disease
Age (in years)
18+
Phase
Phase 2
Participants needed
30
Est. Completion Date
Mar 31, 2025
Treatment type
Interventional
Sponsor
Imara, Inc.
ClinicalTrials.gov identifier
NCT04053803
Study number
IMR-SCD-102-EXT
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?